MiraVista Diagnostics’ dedication to innovation and improved accessibility to high quality fungal diagnostics has created a CE marked Histoplasma Urine Antigen LFA.
MiraVista Diagnostics is leading the industry with a new Histoplasma Urine Antigen LFA. The rapid, non-invasive test has a proven clinical sensitivity of 93.18% and 96.97% specificity relative to culture proven cases, can be operated in low complexity clinical settings and requires no additional equipment.
Review our May 26th, 2020 Press Release regarding this new announcement
Translations